Latest Safety News

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

Vection Technologies capped FY25 with its highest monthly order intake ever, driven by defence and AI/XR contracts, while posting positive pro-forma cash flow despite payment timing issues.

Alexium International Group faced a tough FY25 with declining sales amid a soft US mattress market but is poised for growth in FY26 thanks to technological advances and strategic funding support.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.

Kingsgate Consolidated Ltd reported a robust June quarter with Chatree Gold Mine maintaining gold production above 20,000 ounces and achieving a record All-in Sustaining Cost margin of US$1,240 per ounce. Operational efficiencies and exploration progress position the company well for FY26.

Jupiter Mines reports record FY2025 manganese sales and production at Tshipi mine, while Q4 earnings dip due to lower prices and higher costs. Exxaro’s planned majority acquisition signals a new chapter for the asset.

Robex Resources has successfully listed on the ASX, raising A$120 million to fund its Kiniéro Gold Project in Guinea, which remains on track for first gold production in late 2025. Meanwhile, steady output continues at its Nampala Mine in Mali despite rising costs.

Strategic Elements Ltd has marked significant progress in its Energy Ink™ prototype trials and underground mining technology, maintaining a robust financial footing with $4.21 million cash and no debt.

Lincoln Minerals has identified multiple high-priority drill targets at its Minbrie Copper-Base Metals Project with drilling planned for late 2025, while its Kookaburra Graphite Project achieves battery-grade purity, underscoring the company’s strategic positioning in critical minerals.

Frontier Energy advances its strategic investor process with multiple proposals and prepares bids for the 2025 Capacity Investment Scheme tender, while progressing key development milestones for its Waroona Renewable Energy Project.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.